Scotiabank Initiates Coverage On Syndax Pharmaceuticals with Sector Outperform Rating, Announces Price Target of $39
Portfolio Pulse from richadhand@benzinga.com
Scotiabank analyst George Farmer has initiated coverage on Syndax Pharmaceuticals with a Sector Outperform rating and a price target of $39.
July 27, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals has been given a Sector Outperform rating by Scotiabank with a price target of $39.
The initiation of coverage by Scotiabank with a Sector Outperform rating and a price target of $39 is a positive signal for Syndax Pharmaceuticals. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100